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Abstract
Background: Glucocorticoids inhibit hepatocellular proliferation and modulate the expression of
oncogenes and tumor suppressor genes via mechanisms involving the glucocorticoid receptor.
Glucocorticoids also produce a receptor-mediated inhibitory effect on both basal and hormone-
stimulated expression of a newly discovered family of molecules important for shutting off cytokine
action. We therefore hypothesized that inhibiting glucocorticoid receptors may disturb
hepatocellular growth and apoptosis. Consequently, we investigated the effect of RU486, a potent
antagonist of the glucocorticoid receptor, on basal levels of hepatocellular proliferation and
apoptosis in male B6C3F1 mice. Furthermore, we evaluated the effect of this compound on cellular
genes involved in the regulation of these important processes.
Results: Data show that treatment of male B6F3C1 mice with RU486 (2 mg/kg/d, ip) for 7 days
dramatically inhibited liver cell proliferation by about 45% and programmed hepatocellular death
by approximately 66%. RU 486 also significantly increased hepatic expression of the oncogenes
mdm2 and JunB, while reducing that of the tumor suppressor gene p53.
Conclusion: Exposure to RU486 may ultimately enhance the susceptibility of the liver to cancer
risk by diminishing its ability to purge itself of pre-cancerous cells via apoptosis. This effect may be
mediated through increases in the hepatic expression of the oncogene mdm2, coupled with
decreases in that of the tumor suppressor gene p53. The decrease in hepatocellular proliferation
caused by RU 486 may be related to effects other than its anti-glucocorticoid activity.
Background
RU486 (Mifepristone) has shown remarkable antigluco-
corticoid and antiprogestrone activities both in vitro and
in vivo [1,2]. This compound has a high affinity for ligand
binding sites of both receptors [1,2]. Current clinical uses
of RU486 are limited to its function as a progestrone an-
tagonist [1,2], where it was approved in France in 1988,
and recently in the USA as a means to induce early termi-
nation of pregnancy [1–3].
Based on its antiprogesterone activity, RU486 has been
evaluated as a useful anticancer agent in organs sensitive
to this hormone [4]. Although evidence was not conclu-
sive in these studies, RU486 demonstrated a benefit to hu-
mans suffering from meningioma, breast cancer and
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uterine leiomyomata [4]. Several in vitro studies also dem-
onstrated that RU486 induced antiproliferative effects
against murine mammary tumors [5] as well as cultured
human endometrial stromal and epithelial cells [6,7].
Antagonizing the effects of glucocorticoids by RU486
may, however, result in deleterious effects. Glucocorti-
coids produce a receptor-mediated inhibitory effect on
both basal and hormone-stimulated expression of a newly
discovered family of molecules known as suppressors of
cytokine signalling [8]. These molecules play an impor-
tant role in shutting off cytokine action [8], and RU486
may therefore augment cytokine-mediated effects. Indeed,
since tumor necrosis factor alpha (TNFα) is known to sup-
press hepatic apoptosis [9], a function which is consid-
ered a safeguard mechanism against neoplasia [10,11],
the reported ability of RU486 to elevate hepatic TNFα pro-
duction in vivo and to enhance cell sensitivity to its toxic
effects is alarming [12]. Glucocorticoids also inhibit hepa-
tocellular proliferation [13–15] and modulate the expres-
sion of oncogenes and tumor suppressor genes [11], via
mechanisms involving the glucocorticoid receptor [16–
18], further supporting the notion that inhibiting these re-
ceptors may result in harmful effects.
We tested the hypothesis that inhibition of the glucocorti-
coid receptor will trigger events that may ultimately lead
to liver cancer. Consequently, we investigated the impact
of RU486 on hepatocellular proliferation and pro-
grammed cell death in livers of male B6C3F1 mice, and
quantified hepatic levels of genes involved in these events.
Results
Effect of RU 486 on hepatocellular proliferation and 
apoptosis
In control mice, 1.55 ± 0.12% of hepatocytes were labeled
with BrDU (Fig. 1A). Treatment with RU 486 significantly
diminished these labeling indices by approximately 45%
to 0.86 ± 0.039% (Fig 1A). Similarly, RU 486 caused a re-
markable decrease in programmed cell death in the liver.
In control animals, 2.68 ± 0.7% of hepatocytes were un-
dergoing apoptosis (Fig 1B). These levels were significant-
ly reduced by 66% to 0.9 ± 0.16% in livers of mice
pretreated with RU 486 (Fig 1B).
Increasing oncogene mRNA expression by RU 486
Pretreatment of mice with RU 486 caused significant in-
creases in hepatic levels of JunB and mdm2 (Fig 2). A re-
markable 2.5-fold increase in the mRNA of JunB was
detected upon treatment with RU 486 (Fig 2A). RU 486
also increased the hepatic mRNA levels of the oncogene
mdm2 by 21 ± 7% (Fig 2B).
Decreasing Liver mRNA Levels of c-myc and p53 by RU486
In contrast to its effect on JunB and mdm2 mRNA levels,
RU 486 diminished the hepatic expression of c-myc and
p53 mRNAs to comparable degrees (Fig 3). While mRNA
of c-myc was significantly decreased by approximately 25
± 3% (Fig 3A), that of p53 was also diminished signifi-
cantly by about 21 ± 5% in the livers of animals treated
with RU 486, compared to control mice (Fig 3B).
Discussion
Our results indicate that exposure to the anti-glucocorti-
coid antagonist RU 486 may enhance the potential for
hepatocellular cancer. This conclusion is based on the ob-
served inhibitory impact of RU 486 on programmed liver
cell death.
Effect of RU 486 on liver cell proliferation
Glucocorticoids have been shown in various studies to in-
hibit DNA synthesis [13–15]. Therefore, we hypothesized
that blocking the glucocorticoid receptor by the potent an-
tagonist RU 486 would result in increased incorporation
of BrDU into hepatocyte DNA, indicating an enhanced
cellular proliferative capability. Indeed, RU486 caused a
remarkable 2.5-fold increase in the expression of junB
mRNA (Fig 2A). The protein product of this gene is a
member of the activating protein-1 (AP-1) family [19],
which upon binding to either c-fos or fos B protein form
a complex that have high affinity to AP-1 binding concen-
sus sequence [20]. A wide variety of chemicals, including
growth factors, and tumor promotors increase the expres-
sion of this gene in various cell types [21]. Compared to
untransfected keratinocytes, JunB-transfected cells grew
more rapidly, and were highly invasive in an in vitro assay
[22]. Therefore, the increased hepatic levels of junB gene,
in mice treated with RU486, was expected to reflect an un-
controlled hepatocellular growth in these animals. Sur-
prisingly, however, RU 486 diminished the capacity of
liver cells to proliferate (Fig 1A). In order to explain this
discrepancy, it is noteworthy to mention that unrelated to
its anti-glucocorticoid activity, RU486 also has antioxi-
dant properties that have been suggested to play a role in
the inhibition of cell growth caused by this compound
[7]. Such an effect and/or other anti-glucocorticoid-inde-
pendent influences by RU 486 appears to prevail in rela-
tion to the overall impact of this compound on cell
proliferation, and may indeed suggest, at a first glance, a
protective effect against the risk of hepatocellular cancer.
Diminishing liver capacity to eliminate pre-cancerous 
hepatocytes
Despite the decrease in hepatocellular proliferation
caused by RU 486, inhibition of hepatic apoptosis in ani-
mals treated with this compound (Fig 1B) represents a po-
tentially deleterious effect. Apoptosis is considered a
safeguard that enables an organ to purge itself ofMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/3
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Figure 1
Hepatocellular proliferation (A) and apoptosis (B) in response to RU486. Mice were treated, and cell proliferation as 
well as apoptotic cells were quantified as described under Methods. Data are means ± SEM from 4–6 animals per group.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/3
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Figure 2
Elevated expression of JunB (A) and mdm2 (B) genes in livers of treated animals. Mice were treated and hepatic 
levels of JunB, mdm2 and β-actin were determined as described under Methods. Data are means ± SEM from 3–5 animals per 
group.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/3
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Figure 3
Diminished expression of c-myc (A) and p53 (B) genes in livers of treated animals. Mice were treated and hepatic 
levels of c-myc, p53 and β-actin were determined as described under Methods. Data are means ± SEM from 3–5 animals per 
group.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/3
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transformed cells [10,11], and its inhibition is proposed
as a mechanism by which non-genotoxic hepatocarcino-
gens produce liver cancer [9,23]. We examined the effect
of RU 486 on the hepatic expression of two genes in-
volved in the regulation of this function [10,11], c-myc
and p53, to evaluate how RU486 might inhibit apoptosis.
This compound diminished the hepatic mRNA expression
of both c-myc and p53 significantly (Fig 3). We previously
reported that enhanced liver apoptosis in response to the
antihepatocarcinogen rotenone was preceded and accom-
panied by a marked increase in the hepatic levels of c-myc
mRNA [10], a proto-oncogene that plays a dual role in cell
proliferation and apoptosis [24]. Since in our study [10]
rotenone inhibited hepatocellular proliferation while en-
hancing apoptosis, we concluded that the increase in c-
myc mRNA expression acted as a pro-apoptotic signal in
the liver. Also, p53 modulates a battery of downstream
genes involved in growth control and apoptosis [25,26].
Taken collectively, diminishing liver mRNA levels of both
c-myc and p53 by RU 486 may help define the underlying
reasons for the observed anti-apoptotic activity of this
compound.
In addition to its effects on mRNA of c-myc and p53,
RU486 significantly increased that of the oncogene mdm2
by approximately 20% (Fig 2B). The protein product of
the mdm2 oncogene is over-expressed in a considerable
number of tumors [27]. This protein is a pivotal negative
regulator of p53 [27]; it interacts with the P53 protein
masking its transcriptional domain and accelerating its
proteasomal degradation [21,27]. The later process in-
volves the deacetylation and ubiquitylation of the p53
protein by mdm2 [28]. Inactivation and/or degradation
of p53 diminishes the cell ability to undergo apoptosis
[21]. Conversely, p53 may influence mdm2. Over-expres-
sion of homeodomain-interacting protein kinase 2
(HIPK2), which increases p53 protein expression and/or
stability, leads to a downregulation of mdm2 protein, but
not mRNA [29]. Consequently, the RU486-induced in-
crease in mdm2 mRNA expression, coupled with a de-
crease in that of P53, may also act in tandem to suppress
the liver apoptotic capacity (Fig 1B).
NF-κB and the glucocorticoid receptor
The transcription factor NF-κB plays a critical role in con-
trolling expression of downstream target genes in im-
mune and inflammatory responses, development, and
apoptosis [30]. Important advances have been made in
understanding the signal transduction cascades that con-
trol NF-κB activation. Several lines of evidence indicate
that NF-κB is constitutively activated in cancer cells, sug-
gesting that it plays an important role in tumorigenesis
[30]. Activated glucocorticoid receptors have been shown
to repress NF-κB-mediated gene expression [31], and to
cause a significant reduction in nuclear levels of p65 pro-
tein, a subunit of NF-κB [31]. A variety of mitogens, cy-
tokines, and reactive oxygen intermediates have been
shown to rapidly cause the translocation of NF-κB to the
nucleus [30–32], and the ability of dexamethasone to in-
terfere with this translocation is blocked by prior treat-
ment with the glucocorticoid antagonist RU 486 [30].
Based on these findings, it is plausible to speculate that ex-
posure to RU 486 may interfere with the function of en-
dogenous glucocorticoids as regulators of cell cycle,
allowing the initiation and progression of malignant
transformation of liver cells.
Other mechanisms that may participate in the RU 486-in-
duced inhibition of hepatic apoptosis include the fact that
this compound blocks the inhibitory effect of glucocorti-
coids on suppressors of cytokine signalling in the liver [8].
This family of proteins is induced by growth hormones
and cytokines, and is strongly repressed in vivo by gluco-
corticoids [8]. Up-regulation of these proteins by RU 486
[8], coupled with significant increase in hepatic TNFα lev-
el found in animals treated with RU 486 [12], may con-
tribute to the inhibition of apoptosis observed in our
study (Fig 1B). Increased liver production of TNFα has
been promoted as a significant factor in the mechanism
by which non-genotoxic hepatocarcinogens produce their
effect [9].
Conclusion
RU 486 has recently become available in the USA for clin-
ical use as an effective non-surgical means to induce abor-
tion. The inhibitory effect of this compound on
hepatocellular apoptosis, observed in this study, raises
questions about the potentially deleterious impact of RU
486. A single dose of RU 486 such as that recommended
for abortion, or possible long-term treatment with this
drug in the future for other therapeutic purposes could
potentially initiate events that could increase the risk of
hepatic cancer. Such an effect would be of special concern
for individuals concurrently exposed to other carcinogens.
Methods
Chemicals and supplies
TRI REAGENT was the product of Sigma Chemical Co, St
Louis, MO, while MAXI script™ labeling kit and the Ribo-
nuclease Protection Assay kit were purchased from Ambi-
on, Inc, Austin, TX. 32P UTP was obtained from NEN Life
Science Products, Inc, Boston, MA. ApopTag™ kit was pur-
chased from Intergen (Purchase, NY). Probes for mdm2,
JunB, c-myc and β-actin genes were also obtained from
Ambion, lnc. (Austin, TX).
Animal treatment
Male B6C3F1 mice (Charles River, Portage. Michigan)
weighing 20–25 g were maintained on a daily cycle of al-
ternating 12 hours periods of light and darkness. MiceMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/3
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received the glucocorticoid antagonist RU486 (2 mg/k/
day, ip), or a corn oil vehicle for 7 days. Care and handling
of animals were in accordance with the guidelines of the
USDA through the Animal Welfare Act Guide for the Care
and Use of Laboratory Animals, Department of Health
and Human Services Publication No 85–23.
Ribonuclease protection assay (RPA)
Hepatic RNA was extracted and quantified as we reported
previously [10]. RNA was mixed with 32P-labeled c-myc,
mdm2, p53, JunB, and β-actin probes, then co-precipitat-
ed, purified, and electrophoresed on 5% polyacrylamide
gel. Following electrophoresis, gels were exposed to X-ray
film overnight. Band intensities were quantified using
Molecular Analyst software and a GS-250 Molecular Imag-
er (Bio-Rad Laboratories, Hercules CA).
Hepatocellular proliferation and apoptosis
Bromodeoxyuridine (BrDU) incorporation into DNA, a
measure of cell proliferation, and enzymatic end labeling
of 3'-hydroxy-DNA strand breaks, a measure of apoptosis,
were quantified in situ as we have reported previously
[10].
Statistical analysis
Means of the two experimental groups were compared us-
ing the Student t-test. Statistical significance was defined
as p < 0.05. All data reported are means ± SEM of 3–6 mice
per group.
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